Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human LITAF Anticorps:
anti-Rat (Rattus) LITAF Anticorps:
anti-Mouse (Murine) LITAF Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal LITAF Primary Antibody pour IF, WB - ABIN968613
Moriwaki, Begum, Kobayashi, Matsumoto, Toyoshima, Seya: Mycobacterium bovis Bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein, SIMPLE, that bridges the missing link between lipopolysaccharide and p53-inducible gene, LITAF(PIG7), and estrogen-inducible gene, EET-1. dans The Journal of biological chemistry 2001
Show all 3 Pubmed References
Human Polyclonal LITAF Primary Antibody pour ELISA - ABIN314310
Tang, Metzger, Leeman, Amar: LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: Evidence for LITAF-dependent LPS signaling pathways. dans Proceedings of the National Academy of Sciences of the United States of America 2006
Human Polyclonal LITAF Primary Antibody pour ICC, IF - ABIN4331156
Zhu, Guariglia, Yu, Li, Brancho, Peinado, Lyden, Salzer, Bennett, Chow: Mutation of SIMPLE in Charcot-Marie-Tooth 1C alters production of exosomes. dans Molecular biology of the cell 2013
our findings provide a novel apoptotic regulatory pathway in which LITAF, as a transcription factor, inhibits the expression of BCL6 (Montrer BCL6 Anticorps), which leads to activation of the intrinsic mitochondrial pathway and tumor apoptosis.
In this Chinese Han population a novel Charcot-Marie-Tooth disease-associated gene mutations the LITAF (c.32C>G) was discovered.
Molecular analysis of Charcot-Marie-Tooth 1C revealed five new LITAF/SIMPLE mutations
An aberrant LITAF-phosphoethanolamine interaction on the surface of intracellular membranes contributes to the molecular pathogenesis that underlies Charcot-Marie-Tooth disease type 1C.
Study conclude that LITAF is a monotopic membrane protein whose membrane integration is stabilised by a zinc finger. The related human protein, CDIP1 (cell death involved p53 target 1), displays identical membrane topology, suggesting that this mode of membrane integration is conserved in LITAF family proteins.
PIG7 promotes leukemia cell chemosensitivity via lysosomal membrane permeabilization.
Suggest LITAF as regulatory of pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
LITAF may serve as a switch in the balance between classical and alternative activation in tumor-associated inflammation. (Review)
Results show that LITAF mutants in Charcot-Marie-Tooth 1C have an altered intracellular localization. They localize either completely or partially in the mitochondria depending on the mutation site. This can explain the different severity of the disease.
Study shows that the I92V LITAF sequence variant would be a good candidate for a biomarker in the case of the CMT1A/HNPP (Montrer PMP22 Anticorps) disorders.
Data suggest that atypical inflammatory signaling kinetics may account for the gain of function elicited by the Litaf protein SIMPLE mutation in Charcot-Marie-Tooth Type 1C (CMT1C) patients.
Mutation of SIMPLE (Litaf) in Charcot-Marie-Tooth 1C alters production of exosomes.
This study demonistrated that loss of Litaf function is unlikely to be a major contributor to Charcot-Marie-Tooth disease, but modulating effects of macrophages need to be considered in the etiology of the disease.
In LITAF-deficient mice, mLITAF-mediated CCL2 (Montrer CCL2 Anticorps) production in macrophages was significantly reduced compared to the wild-type control animals
Study provides evidence that LITAF contributes to the regulation of TNF-alpha (Montrer TNF Anticorps) in LPM harvested following acute inflammation.
Whole-body deletion of LPS-induced TNF-alpha factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis.
the regulation of LITAF/TNF-alpha by p53 (Montrer TP53 Anticorps) and its short peptide 162-motif
PTP4A3 (Montrer PTP4A3 Anticorps) was identified as a novel negative regulator of LPS (Montrer TLR4 Anticorps)-induced LITAF/TNF-alpha production.
LITAF is an important mediator of the LPS (Montrer TLR4 Anticorps)-induced inflammatory response.
Lipopolysaccharide is a potent stimulator of monocytes and macrophages, causing secretion of tumor necrosis factor-alpha (TNF-alpha) and other inflammatory mediators. This gene encodes lipopolysaccharide-induced TNF-alpha factor, which is a DNA-binding protein and can mediate the TNF-alpha expression by direct binding to the promoter region of the TNF-alpha gene. The transcription of this gene is induced by tumor suppresor p53 and has been implicated in the p53-induced apoptotic pathway. Mutations in this gene cause Charcot-Marie-Tooth disease type 1C (CMT1C) and may be involved in the carcinogenesis of extramammary Paget's disease (EMPD). Multiple alternatively spliced transcript variants have been found for this gene.
LPS-induced TNF-alpha factor
, lipopolysaccharide-induced TNF-alpha factor
, lipopolysaccharide-induced tumor necrosis factor-alpha factor
, p53-induced gene 7 protein
, small integral membrane protein of lysosome/late endosome
, tumor protein p53 inducible protein 7
, LPS-induced TN factor
, LPS-induced TNF-alpha factor homolog
, estrogen-enhanced transcript protein 1
, estrogen-responsive uterine transcript
, lipopolysaccharide-induced tumor necrosis factor-alpha factor homolog
, TNF-alpha factor
, lipid-induced TNF-alpha factor
, tissue necrosis factor-alpha
, LITAF-like protein
, Nedd4 WW domain-binding protein 3
, estrogen-enhanced transcript protein